Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Drugmakers Face Rising Costs to Prepare for ‘No Deal’ Brexit

Nov. 29, 2018, 1:50 PM

U.K.-based drug companies face mounting costs in preparing for the U.K. to leave the EU without any trading arrangements, they said at a Nov. 28 parliamentary hearing.

Multinationals AstraZeneca plc and GSK Group are among the companies that have been forced to build duplicate laboratories for batch testing of medicines in their EU sites, Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry, said. They’re facing export restrictions on U.K.-made drugs under a “no deal” Brexit.

“They are clearly very frustrated about this because it is essentially duplicating what is available” in the U.K., he said.

Pfizer ...